Evidence map›Paper›PMID 20401731›Full record

ArticleJournal of neural transmission (Vienna, Austria : 1996)2010

No increased chromosomal damage in L-DOPA-treated patients with Parkinson's disease: a pilot study.

Rajaraman Gnana Oli, Gholamreza Fazeli, Wilfried Kuhn, Susanne Walitza, Manfred Gerlach, Helga Stopper

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neural transmission (Vienna, Austria : 1996), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 24 citations in OpenAlex.

  1. Micronuclei: origins, assays, mechanisms, diseases and treatments.Signal transduction and targeted therapy · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Oxidized extracellular DNA as a stress signal in human cells.Oxidative medicine and cellular longevity · 2013
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Rajaraman Gnana OliDepartment of Toxicology, University of Wuerzburg, Versbacher Strasse 9, 97078 Wuerzburg, Germany.
Gholamreza Fazeli
Wilfried Kuhn
Susanne Walitza
Manfred Gerlach
Helga Stopper
University of Würzburg · DELeopoldina Krankenhaus Schweinfurt · DEUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is a neurodegenerative movement disorder affecting about 2% of the human population in old age. L-3,4-Dihydroxyphenylalanine (L-DOPA) in combination with a peripheral aromatic amino acid decarboxylase inhibition has been the most frequently prescribed drug for alleviating symptoms of PD, but a potential contribution of L-DOPA therapy to further neurodegeneration via oxidative stress is still debated. We report that the specific oxidative stress biomarker 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) level in peripheral blood lymphocyte DNA was elevated to 8.1 +/- 1.7 8-oxodG/10(6)dG in 17 chronically L-DOPA-treated PD patients, compared to 4.6 +/- 1.2 8-oxodG/10(6)dG in 12 controls. However, the total antioxidative capacity of plasma was increased to 1113 +/- 237 microM in the PD patients compared to 941 +/- 254 microM in controls. The frequency of micronuclei, a subgroup of chromosomal aberrations, in peripheral blood lymphocytes was not elevated compared to healthy age-matched individuals. In vitro, in a cell-free assay, dopamine and its precursor L-DOPA exhibited antioxidative capacity. On the other hand, the 8-oxodG concentration in cultured PC 12 cells was enhanced after dopamine treatment. This elevation may be below a threshold for manifestation as chromosomal damage.

Indexed as

8-Hydroxy-2'-DeoxyguanosineAgedAged, 80 and overAnimalsAntiparkinson AgentsCells, CulturedChromatography, LiquidChromosomesDeoxyguanosineDose-Response Relationship, DrugDrug Therapy, CombinationEnzyme InhibitorsFemaleFluorescence Recovery After PhotobleachingHumansLevodopa8-Hydroxy-2'-DeoxyguanosineAntiparkinson AgentsDeoxyguanosineEnzyme InhibitorsLevodopa

Identifiers

PMID20401731
OpenAlexW2025787824

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.